Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions

Fineline Cube May 22, 2026
Company Deals

Johnson & Johnson Partners with Abu Dhabi DOH to Launch Global Surgical Intelligence Network Powered by Polyphonic Platform

Fineline Cube May 22, 2026
Company Deals

Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform

Fineline Cube May 22, 2026
Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Eli Lilly’s Retatrutide Delivers Breakthrough Weight Loss Results in Phase 3 TRIUMPH-1 Trial for Obesity Treatment

Fineline Cube May 22, 2026
Company Drug

Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer

Fineline Cube May 22, 2026
Company Drug

Shenzhen Chipscreen Advances CS231295 for Cancer Treatment as IND Accepted by NMPA

Fineline Cube Oct 19, 2024

On October 17, Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that its innovative Class...

Company Deals

Pfizer Partners with TRIANA Biomedicines to Develop Molecular Glue Degraders for Oncology and Other Diseases

Fineline Cube Oct 18, 2024

Pfizer (NSE: PFIZER), a leading US pharmaceutical company, has entered into a strategic partnership and...

Company Drug

AstraZeneca Files for Market Approval of Tremelimumab in China for Hepatocellular Carcinoma

Fineline Cube Oct 18, 2024

The Center for Drug Evaluation (CDE) has indicated on its website that AstraZeneca (NASDAQ: AZN),...

Company Medical Device

MicroPort CardioFlow’s Heart Valve Balloon Dilatation Catheter Alwide Plus Gains Mexican Approval

Fineline Cube Oct 18, 2024

MicroPort Scientific Corp., a leading Chinese medical device company (HKG: 0853), through its spin-off MicroPort...

Company Drug

Changshan Biochemical Pharmaceutical Wins Marketing Approval for Enoxaparin in Niger

Fineline Cube Oct 18, 2024

Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255), a Chinese pharmaceutical company, has announced...

Company Drug

Huahai Pharmaceutical Gets FDA Nod for Generic Empagliflozin and Metformin ANDA

Fineline Cube Oct 18, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a prominent Chinese pharmaceutical company, has announced the...

Company Drug

Laekna Advances Obesity Treatment Candidate LAE102 with Subcutaneous Dosing in Phase I Study

Fineline Cube Oct 18, 2024

Laekna, a Sino-US biotech firm, has announced the commencement of a subcutaneous dosing cohort within...

Company Deals

Sanofi Invests EUR 300 Million in Joint Venture with Orano Med for Next-Generation Radioligand Therapies

Fineline Cube Oct 18, 2024

Sanofi (EPA: SAN), a leading French pharmaceutical company, has entered into a strategic agreement with...

Company Drug

Antengene’s Xpovio Secures Expanded Access in South Korea for Multiple Myeloma Treatment

Fineline Cube Oct 18, 2024

Antengene Corp., Ltd (HKG: 6996), a China-based biopharmaceutical company, has announced that it has received...

Company Drug

AbbVie’s Vyalev Wins FDA Approval as First Subcutaneous Levodopa Therapy for Advanced Parkinson’s

Fineline Cube Oct 18, 2024

AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the US, has received approval from...

Policy / Regulatory

Chengdu Drafts Comprehensive Policy to Stimulate Biomedical Industry Growth

Fineline Cube Oct 18, 2024

The Chengdu Municipal Bureau of Economic and Information Technology has unveiled a draft proposal titled...

Company Drug

Chongqing Zhifei Biological’s EC Injection Receives Market Approval in Indonesia

Fineline Cube Oct 18, 2024

Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a leading biopharmaceutical company based in China, has...

Company Deals

Tencent Invests USD 30 Million in Early Cancer Detection Firm Insighta, Backed by Prenetics

Fineline Cube Oct 18, 2024

Prenetics Global Limited (NASDAQ: PRE), a prominent health sciences company with operations in the US...

Company Deals

LaNova Medicines Secures RMB 300 Million in Series C1 Financing to Advance Cancer Therapy Pipeline

Fineline Cube Oct 18, 2024

LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the successful completion of...

Company

Abbott Laboratories Posts 9.4% Q3 Sales Growth, Driven by Medical Devices and Pharmaceuticals

Fineline Cube Oct 18, 2024

Abbott Laboratories (NYSE: ABT), a U.S.-based healthcare giant, has reported its financial results for the...

Company Deals

Chengdu Baiyu Pharmaceutical Strikes Licensing Deal with Novartis for Unannounced Anti-Tumor Asset

Fineline Cube Oct 18, 2024

Chengdu Baiyu Pharmaceutical Co., Ltd., a Chinese pharmaceutical company, has entered into a licensing agreement...

Company Deals

Cryofocus Medtech Partners with Guangzhou Medical University Hospital for Cryoballoon Ablation R&D

Fineline Cube Oct 17, 2024

Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based leader in cryoablation treatment, and the...

Company Drug

Kintor Pharmaceutical Initiates Phase II/III Trial for KX-826 Tincture 1.0% in Treating Male Androgenetic Alopecia

Fineline Cube Oct 17, 2024

Kintor Pharmaceutical Ltd (HKG: 9939), a biopharmaceutical company based in China, has announced the commencement...

Company Medical Device

Novocure’s Optune Lua Wins FDA Approval for mNSCLC Treatment in Combination with Immunotherapies

Fineline Cube Oct 17, 2024

Novocure (NASDAQ: NVCR), a Swiss firm renowned for its pioneering Tumor Treating Fields (TTFields) cancer...

Company Deals

Servier and HUST Forge Partnership to Cultivate Innovative Therapies through SHINEDocs Program

Fineline Cube Oct 17, 2024

French pharmaceutical company Servier has joined forces with Huazhong University of Science and Technology (HUST),...

Posts pagination

1 … 286 287 288 … 670

Recent updates

  • Eli Lilly’s Retatrutide Delivers Breakthrough Weight Loss Results in Phase 3 TRIUMPH-1 Trial for Obesity Treatment
  • Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer
  • Astellas and MSD’s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU
  • Hansoh Pharma’s HS-10504 Receives NMPA Breakthrough Therapy Designation for Fourth-Generation EGFR Inhibitor in Resistant NSCLC
  • Bayer’s Kerendia Receives FDA Priority Review for Expanded Indication in Type 1 Diabetes-Associated Chronic Kidney Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Eli Lilly’s Retatrutide Delivers Breakthrough Weight Loss Results in Phase 3 TRIUMPH-1 Trial for Obesity Treatment

Company Drug

Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer

Company Drug

Astellas and MSD’s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU

Company Drug

Hansoh Pharma’s HS-10504 Receives NMPA Breakthrough Therapy Designation for Fourth-Generation EGFR Inhibitor in Resistant NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.